ClinicalTrials.gg
RecruitingNCT04771130Updated Sep 14, 2026

A Study of BGB-11417 in Participants With Myeloid Malignancies

A Phase 1/2 interventional study of BGB-11417 and Azacitidine in Acute Myeloid Leukemia, Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasm, sponsored by BeOne Medicines. Recruiting at 47 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by BeOne Medicines · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started May 2021; still recruiting 5 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
260
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 265 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.

Planned enrollment
37th of 433
260 · median 50
Started
2021
with 43 others
Phase 1/2
66 of 473
39 open now
Primary completion
2028-08
later than 248 of 288 live
Registered
128th of 473
by date

Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 37th largest by planned enrollment of the 433 interventional ones that give a count, is one of 44 that started in 2021, is one of 66 in phase 1/2, reaches primary completion later than 248 of the 288 other live ones, and was the 128th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

265 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:

260 more — sign in →

All 265 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 473 studies in Leukemia, Myeloid, Acute with a site in China, or all of them as a file.
02

Study summary

The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .

Read the detailed description

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

03

Conditions studied

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Myelodysplastic/Myeloproliferative Neoplasm

Keywords

  • BGB-11417
  • Azacitidine
  • Posaconazole
  • AML
  • MDS
  • MDS/MPN
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Confirmed diagnosis of one of the following by 2016 World Health Organization criteria:

    • AML, nonacute promyelocytic leukemia
    • MDS
    • MDS/MPN
  2. performance status of 0 to 2.
  3. Adequate organ function defined as:

    • ≥ 50 milliliters/minute (mL/min) (or between 30 and 49 mL/min in unfit AML cohort)
    • Adequate liver function
  4. of > 12 weeks.
  5. Ability to comply with the requirements of the study.

Key Exclusion Criteria:

  1. A diagnosis of acute promyelocytic leukemia.
  2. History of prior , with the exception of either a history of MDS or MDS/MPN that has transformed to AML, or other prior malignancy that was treated with a full curative intent and no evidence of recurrence within the past 2 years (eg, localized skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score ≤ 6 prostate cancer)
  3. Antecedent MPN including myelofibrosis, essential thrombocytosis, polycythemia vera, or chronic myelogenous leukemia with or without BCR-ABL1 translocation and AML with BCR-ABL1 translocation.
  4. Prior therapy with a B-cell lymphoma-2 inhibitor
  5. Known central nervous system involvement by leukemia.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Parts 1 and 2: AML Cohorts

    Participants with AML will receive BGB-11417 and azacitidine on a 28-day cycle.

    Drug: BGB-11417 · Drug: Azacitidine

  • Experimental
    Parts 1 and 2: MDS Cohorts

    Participants with MDS will receive BGB-11417 and azacitidine on a 28-day cycle.

    Drug: Azacitidine · Drug: BGB-11417

  • Experimental
    Part 3: AML and MDS Cohorts

    Participants with AML and MDS will receive BGB-11417 and azacitidine on a 28-day cycle. A subset of the participants will receive a modified second cycle of treatment to explore drug-drug interactions (DDI) with posaconazole.

    Drug: BGB-11417 · Drug: Azacitidine · Drug: Posaconazole

  • Experimental
    Part 3: AML and MDS Cohort

    Participants with MDS and R/R AML (China only) will receive BGB-11417 on a 28-day cycle.

    Drug: BGB-11417

Interventions

  • Oral administration for 10, 21, 14 or 28 days on a 28-day cycle.

    Also known as: Sonrotoclax

  • Intravenous or subcutaneous administration for 7 days.

  • Oral administration for 8 days on second cycle only.

  • Oral administration for 28 days on a 28-day cycle.

  • Oral administration for 10, 14 or 21 days on a 28-day

06

What researchers measure

Primary outcomes

  1. Part 1 And 2: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)

    Time frame: Cycle 1 (Up to 28 days for non-hematologic DLTs and up to 42 days for hematologic DLTs)

  2. Part 1 And 2: Number Of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    Time frame: Approximately 24 months

  3. Part 3 AML Cohort: Complete Remission (CR) Plus CR With Partial Hematologic Recovery (CRh) Rate

    CR plus CRh will be defined as the percentage of participants whose best overall response (BOR) is CR plus CRh. BOR will be defined as the best response recorded from the first dose of study drug until data cut or the initiation of new anticancer treatment.

    Time frame: Approximately 24 months

  4. Part 3 MDS Cohort: Modified Overall Response (mOR) Rate

    The mOR will be defined as the percentage of participants whose BOR is achieving CR, marrow complete remission (mCR), or partial remission (PR) at any time point during the study for myelodysplastic/myeloproliferative neoplasm (MDS/MPN).

    Time frame: Approximately 24 months

  5. Part 3 AML Cohort (DDI Sub-cohort): Area Under Plasma Concentration-time Curve (AUC) from time 0 to the last quantifiable timepoint (t) (AUC0-t) Of BGB-11417 When Administered Alone and when Co-administered With Posaconazole

    Time frame: Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 2, 4, 6, 8, and 24 hours postdose)

  6. Part 3 AML Cohort (DDI Sub-cohort): Maximum Observed Plasma Concentration (Cmax) Of BGB-11417 When Administered Alone and When Co-administered With Posaconazole

    Time frame: Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 2, 4, 6, 8, and 24 hours postdose)

  7. Part 3 AML Cohort (DDI Sub-cohort): Area Under Plasma Concentration-time Curve (AUC) from time 0 to infinity (AUC0-infinity) Of BGB-11417 When Administered Alone and When Co-administered With Posaconazole

    Time frame: Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, , 4, 6, 8, and 24 hours postdose)

  8. Part 3 AML and MDS Cohorts (Treated with Monotherapy): Number Of Participants Experiencing DLTs

    Time frame: Cycle 2

  9. Part 3 AML and MDS Cohorts (Treated with Monotherapy): Number of Participants Experiencing TEAEs

    Time frame: Approximately 24 months

Secondary outcomes

  1. Parts 1 And 2 AML Cohort: Complete remission (CR) + Morphologic CR With Partial Hematologic Recovery (CRh)

    Time frame: Approximately 24 months

  2. Parts 1 And 2 MDS Cohort: mOR Rate

    Time frame: Approximately 24 months

  3. Parts 1 And 2: Cmax Of Azacitidine When Coadministered With BGB-11417

    Time frame: Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose

  4. Parts 1 And 2: Terminal Half-life (t1/2) Of Azacitidine When Coadministered With BGB-11417

    Time frame: Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose

  5. Parts 1 And 2: AUC From Time Zero To Time t (AUC0-t) Of Azacitidine When Coadministered With BGB-11417

    Time frame: Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose

  6. Parts 1 And 2: AUC From Time Zero To Infinity (AUC0-inf) Of Azacitidine When Coadministered With BGB-11417

    Time frame: Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose

  7. Parts 1 And 2: Apparent Total Clearance Of Azacitidine From Plasma (CL/F) When Coadministered With BGB-11417

    Time frame: Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose

  8. Parts 1 And 2: Apparent Volume Of Distribution (Vz/F) Of Azacitidine When Coadministered With BGB-11417

    Time frame: Day 0 and 4 (Cycle 1) predose and at multiple time points up to 4 hours postdose

  9. Parts 1 And 2: Steady-state AUC From Time Zero To Time Of Last Measurable Concentration (AUClast,ss) Of BGB-11417 When Coadministered With Azacitidine

    Time frame: Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose

  10. Parts 1 And 2: Steady-state Cmax (Cmax,ss) Of BGB-11417 When Coadministered With Azacitidine

    Time frame: Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose

  11. Parts 1 And 2: Steady-state Trough Plasma Concentration (Ctrough,ss) Of BGB-11417 When Coadministered With Azacitidine

    Time frame: Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose

  12. Parts 1 And 2: Steady-state Time To Maximum Observed Plasma Concentration (tmax,ss) Of BGB-11417 When Coadministered With Azacitidine

    Time frame: Day 1-4 and 28 (Cycle 1) Day 5 (Cycle 2) predose and at multiple time points up to 8 hours postdose

  13. Part 3: Number Of Participants Experiencing TEAEs

    Time frame: Approximately 24 months

  14. Part 3: Complete Response Rate

    CR will be defined as the percentage of participants whose BOR is CR. BOR will be defined as the best response recorded from the first dose of study drug until data cut or the initiation of new anticancer treatment.

    Time frame: Approximately 24 months

  15. Part 3 AML Cohort: CR With Incomplete Hematologic Recovery (CRi) Rate

    CRi will be defined as the percentage of participants whose BOR is CRi.

    Time frame: Approximately 24 months

  16. Part 3 AML Cohort: Overall Response Rate (ORR)

    The ORR will include participants whose BOR include CR, CRi, PR, and morphologic leukemia-free state.

    Time frame: Approximately 24 months

  17. Part 3 AML Cohort: Duration Of Response (DOR)

    DOR will be defined as the time from the first response to disease progression documented after treatment initiation or death, whichever occurs first. DOR will include CR, CR plus CRi, overall response (OR), and CR plus CRh.

    Time frame: Approximately 24 months

  18. Part 3 AML Cohort: Time To Response (TTR)

    TTR will be defined as the time from treatment initiation to the first documented response and will include CR, CR plus CRi, OR, and CR plus CRh.

    Time frame: Approximately 24 months

  19. Part 3 Event-free Survival (EFS)

    EFS will be defined as the time from treatment initiation to disease progression, treatment failure, relapse (hematologic relapse for AML) for those who have treatment success, or death due to any cause, whichever happens first.

    Time frame: Approximately 24 months

  20. Part 3 Overall Survival (OS)

    OS will be defined as the time from treatment initiation to death. OS will be analyzed using the same methods as the EFS analysis except for the censoring rules.

    Time frame: Approximately 24 months

  21. Part 3 AML Cohort: Number of Participants with Transfusion Independence

    Transfusion independence will be defined as the proportion of participants whose BOR is transfusion independence. Transfusion independence will need to last for at least 56 consecutive days postbaseline.

    Time frame: Approximately 24 months

  22. Part 3 MDS Cohort: Number Of Participants With Hematological Improvement-erythroid (HI-E)

    The proportion of participants whose BOR is HI-E

    Time frame: Approximately 24 months

  23. Part 3 MDS Cohort: Proportion Of Participants With Hematological Improvement-platelet (HI-P)

    The proportion of participants whose BOR is HI-P

    Time frame: Approximately 24 months

  24. Part 3 MDS Cohort: Proportion Of Participants With Hematological Improvement-neutrophil (HI-N)

    The proportion of participants whose BOR is HI-N will be reported.

    Time frame: Approximately 24 months

  25. Part 3 MDS Cohort: Number of participants with Transfusion Independence

    Transfusion independence will be defined as the percentage of participants whose BOR is transfusion independence. Transfusion independence will need to last for at least 56 consecutive days postbaseline.

    Time frame: Approximately 24 months

  26. Part 3: Ctrough,ss Of BGB-11417 When Coadministered With Azacitidine

    Time frame: Cycle 1 Day 1 and Cycle 2 Day 5 (predose and 4 and 6 hours postdose)

  27. Part 3 MDS cohort: Partial Hematologic Recovery CRh

    Percentage of participants with partial hematologic recovery will be reported

    Time frame: Approximately 24 months

  28. Part 3 AML (Treated with Monotherapy): Complete Response + Morphologic complete Remission with Partial Hematologic Recovery

    Percentage of participants with Complete Response + Morphologic complete Remission with Partial Hematologic Recovery will be reported.

    Time frame: Approximately 24 months

  29. Part 3 AML (Treated with Monotherapy): Steady State trough plasma concentration of BGB-11417

    Time frame: Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 4, 6, 8, and 24 hours postdose)

  30. Part 3 MDS (Treated with Monotherapy): Modified Overall Response

    Percentage of participants with modified overall response including CR, marrow CR (mCR) or partial remission (PR)

    Time frame: Approximately 24 months

  31. Part 3 MDS (Treated with Monotherapy): Steady State trough plasma concentration of BGB-11417

    Time frame: Cycle 2 Day 12 and Cycle 2 Day 20 (predose and 1, 4, 6, 8, and 24 hours postdose)

07

Study locations

42 of 47 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beonemedicines.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Aug 2028, 87 months after the start.

Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's planned 87 months is above that.

Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2021
First posted
Feb 25, 2021
StartActual
May 24, 2021
Primary completionEst.
Aug 31, 2028
CompletionEst.
Aug 31, 2028
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04771130
Lead sponsor
BeOne Medicines
Responsible party
Sponsor
First posted
Feb 25, 2021
Start date
May 24, 2021
Primary completion
Aug 31, 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Sep 14, 2026

Study contacts

Study Director
Contact
clinicaltrials@beonemed.com
1.877.828.5568
Study Director
study director · BeOne Medicines

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonrotoclax

Start the discussion